Strotsev 30s 500 500 mg film-coated tablets

The instruction for medical use of Strotsit medicine 500 the Trade name of Strotsit 500 International unlicensed name Tsitikolin Lekarstvennaya the Tablet form, film coated, 500 mg Structure One tablet contains active agent – Tsitikolina of sodium-523.600 (equivalent tsitikolinu-500.000), excipients: cellulose microcrystalline (PH 101), starch corn, povidone (To 30), the talc purified, silicon colloidal anhydrous, sodium of a kroskarmelloz (Primoloz), magnesium stearate, water the cleaned Cover: Opadri brown 06F86813: a hydroksipropilmetiltsellyuloza (Gipromelloza 2910) (E 464) 5sr, a hydroksipropilmetiltsellyuloza (Gipromelloza 2910) (E 464) 15sr, the titan dioxide (E 171), makrogol / polyethyleneglycol (E 1521), gland (III) oxide yellow (E 172), talc (E 553b), the water purified the Description of the Tablet of a capsulovidny form with a biconvex surface of red color, film coated with dividing risky on one party and flat with another Pharmacotherapeutic group of Psikhoanaleptiki. Psychostimulants and nootropa. Psychostimulants and nootropa others. Tsitikolin ATH N06BX06 Code the Pharmacological Pharmacokinetics Tsitikolin properties is well absorbed at intake. Absorption after oral administration almost full, bioavailability is about 99%. Drug is metabolized in intestines and in a liver with formation of sincaline and cytidine. The liver can synthesize lecithin from sincaline and repeatedly synthesize tsitikolin from cytidine and sincaline After administration of drug the concentration of sincaline in plasma significantly increases. Tsitikolin is substantially distributed in structures of a brain, with rapid implementation of fractions of sincaline in structural phospholipids and fractions of cytidine – in cytidine nucleotides and nucleic acids. Tsitikolin gets into a brain and is actively built in cellular, cytoplasmic and mitochondrial membranes, forming a part of fraction of structural phospholipids. Only 15% of the entered dose of a tsitikolin are brought out of an organism: 2%-3% - kidneys, less than 1% through intestines and about 12% with the exhaled CO2 (carbon dioxide). In excretion of a tsitikolin with urine it is possible to allocate 2 phases: the first phase lasting about 36 hours during which clearance rate decreases and the second phase during which the speed of excretion decreases much more slowly. The same is observed with the exhaled CO2 - clearance rate quickly decreases approximately in 15 hours, and then decreases much more slowly. Pharmacodynamics. Strotsit - nootropic drug, active ingredient tsitikolin is pirimidinovy 5 '-a nucleotide which serves as an important precursor in the course of synthesis of lecithin (phosphatidylsincaline) and other phospholipids. Improves transfer of nervous impulses in cholinergic neurons - positively influences plasticity of neuronalny membranes and function of receptors. Improves a cerebral blood stream, strengthens metabolic processes in a brain, activates structures of a reticular formation of a brain and restores consciousness in a traumatic brain damage. Strotsit is a sincaline source, increasing synthesis of acetylcholine and stimulates biosynthesis of structural (basic) phospholipids in a membrane of neurons that promotes improvement of function of membrane mechanisms, including, to functioning of ion-exchange pumps and the receptors shipped in them which modulation is a necessary condition of neurotransfer. Strotsit softens the symptoms which are observed in a hypoxia and ischemia of a brain, including a memory impairment, emotional lability, lack of initiative, difficulties during the performing of daily actions and self-service. Strotsit it is effective in treatment of cognitive, sensitive and motive neurologic disorders of a degenerative and vascular etiology. Indications - treatment of complications and consequences of disturbances of cerebral circulation - a craniocereberal injury and its consequences - the cognitive, sensitive, motor and neurologic disorders caused by cerebral pathology of degenerative and vascular origin in dementia the Route of administration and doses Adult the Dose has to be picked up individually. The recommended dosage from 500 to 1000 mg a day (1 – 2 tablets), depending on disease severity. People of advanced age correction of a dosage for this age group is not required. Side effects Very seldom (& lt, 1/10.000) (including individual reactions). - allergic reactions, a small tortoiseshell, a dieback, erubescence up to purple coloring, a skin itching, hypostases, development of an acute anaphylaxis - a headache, dizziness, fatigue, hallucinations, excitement, insomnia, temperature increase, feeling of heat, a tremor - dispnoe - nausea, vomiting, diarrhea - increase or short-term lowering of arterial pressure of the Contraindication - hypersensitivity to drug components is possible - a state with a high tone of parasympathetic nervous system (vagotonia) Medicinal interactions Tsitikolin enhances effects of L-dihydroxyphenylalanin. It is not necessary to appoint along with the medicines containing meklofeksonat. Special instructions Tsitikolin can cause hypotension. Use in pediatrics Is not present sufficient data concerning use of a tsitikolin to children therefore it is not recommended to appoint Strotsit of this age category of patients. Pregnancy and the period of a lactation the Corresponding well controlled researches of a tsitikolin during pregnancy and a lactation are absent. During pregnancy tsitikolin it is necessary to apply, only if the potential advantage justifies presence of potential risk for a fruit. The care when feeding is necessary a breast as it is unknown whether it is allocated tsitikolin in breast milk. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms Considering side effects it is necessary to be careful at control of motor transport or work with other mekhan_zma. Overdose Symptoms: strengthening of side effects of drug. Treatment: symptomatic. A form of release and packing On 10 tablets in planimetric bezjyacheykovy packing from aluminum foil. On 3 planimetric bezjyacheykovy packs together with the instruction for medical use in the state and Russian languages place in a cardboard box. Storage conditions In the dry, protected from light place, at a temperature not over 25 ºС. To store out of children's reach! 3 years not to use a period of storage after an expiration date. Prescription status According to the prescription Sun Pharmaceutical Industries Ltd Producer. Legal address: Sun House, Plot No. 201 B/1, Western Express Highway, Goregoan (E), Mumbai - 400,063, Maharashtra, India the Address of location of production: Survey No. 214, Plot No. 20, Govt. Ind. Area, Phase II, Silvassa – 396230 U.T. of Dadra and Nagar Haveli, India the Name and the country of the owner of the registration certificate of Sun Pharmaceutical Industries Ltd., India the Name and the country of the organization of the packer of Sun Pharmaceutical Industries Ltd, India the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) 050008, Kazakhstan, Almaty Manas St. 32 And, Business center SAT 6 the floor, office 602